[Investor Note 投資者簡訊] China Biotech Services (8037.HK) Sunrise Diagnostic Centre under China Biotech Services sets up a Joint Venture Laboratory with Town Health International Medical Group
* * * *
Bringing laboratory test services to the clinical network for the masses
Broadening service channels to enhance business growth
中國生物科技服務(8037.hk) 附屬華昇診斷中心與康健國際成立合營實驗室
* * * *
透過診所網路提供檢測服務 拓展服務渠道 加快業務增長
（香港，2022年3月14日）— 中國生物科技服務控股有限公司（「中國生物科技服務」或「集團」；股份代號：8037.HK）於3月11 日公佈，其附屬公司華昇診斷中心有限公司（「華昇診斷中心」）與康健國際醫療集團有限公司（「康健國際」；股份代號：3886.HK）之全資附屬公司成立合營公司，華昇診斷中心將持有合營公司51%的股份。合營公司將在香港經營醫學實驗室，為公眾客戶提供包括COVID-19核酸檢測的檢測服務。集團透過成立合營公司與全港其中一家最大醫療集團結盟，實行優勢互補，為旗下檢測業務的長遠可持續發展提供動力。
(Hong Kong, 14 March 2022) - China Biotech Services Holdings Limited ("China Biotech Services" or the "Group"; stock code: 8037.HK) announced on 11 March that Sunrise Diagnostic Centre Limited (華昇診斷中心有限公司; “Sunrise”), a subsidiary of the Group, will set up a joint venture company (“JV Company”) with a wholly-owned subsidiary of Town Health International Medical Group Limited (“Town Health Group”; stock code: 3886.HK), in which Sunrise will hold a 51% stake. The JV Company will be engaged in the operation of a medical laboratory (“Laboratory”) in Hong Kong to carry out, among other testing services, COVID-19 nucleic acid testing services for general public clients. The Group formed an alliance with one of the largest medical groups in Hong Kong through the establishment of a joint venture to complement each other's advantages, creating momentum for the long-term sustainable development of its testing business.
華昇診斷中心與康健國際成立合營公司，將可把華昇診斷中心之COVID-19核酸檢測服務迅速在新冠疫情爆發期間伸延至香港其中一個最大的私營醫療服務網絡。透過增加產品組合及服務全醫療巿場，推動集團業務在後疫情時代持續增長，並擴大巿場佔有率。從長遠角度來看，透過雙方共同努力，將能迎合香港巿場對多種檢測服務的殷切需求。
The formation of the JV Company between Sunrise and the Town Health Group will extend the reach of Sunrise’s COVID-19 nucleic acid testing services to one of the largest private healthcare service networks amid the COVID-19 pandemic in Hong Kong. By enriching the product portfolio and serving the entire medical market, the Group will be able to grow its business and expand its market share in the post-pandemic era. In the long term, it is expected that Sunrise and Town Health Group will work together to develop the Laboratory into one that can cater for other highly demanded medical testing services in Hong Kong
華昇診斷中心從事醫學實驗室檢測服務，並為其中一家香港政府認可進行 COVID-19核酸檢測的本地醫療檢測機構，由集團之直接全資附屬公司Grande Fortune International Limited、華大基因健康科技（香港）有限公司（其實益擁有人為深圳華大基因股份有限公司（深圳證券交易所股份代號：300676.SZ）），以及在香港醫療系統擁有豐富管理經驗之醫療行業領袖胡定旭先生擁有。
Sunrise is engaged in medical laboratory testing services and is one of the local COVID-19 nucleic acid testing institutions recognised by the Government of Hong Kong. It is owned by Grande Fortune International Limited, a direct wholly-owned subsidiary of the Group, BGI Health (HK) Company Limited (the beneficial owner of BGI is 深圳華大基因股份有限公司 (SZSE Stock Code: 300676.SZ)), and Mr. Wu Ting Yuk Anthony, a leader in the healthcare industry who has extensive management experience in the medical system of Hong Kong.
有關中國生物科技服務控股有限公司（股份代號：8037.HK）
中國生物科技服務控股有限公司在香港聯交所創業板上市，並於2018年5月納入香港MSCI微型股指數。集團專注於兩個主要領域，主要針對精准診斷和細胞治療。集團還在細胞治療研發、醫學檢測、癌症精准診斷等領域開展業務。
About China Biotech Services Holdings Limited (Stock Code: 8037.HK)
China Biotech Services Holdings Limited is listed on GEM of Hong Kong Stock Exchange and was included in MSCI Hong Kong Micro Cap Index in May 2018. The Group focuses on two main areas which primarily aim towards precision diagnosis and cellular therapeutics. The Group also has businesses in cellular therapeutics R&D, medical testing, cancer precision diagnosis and other areas.